^
Association details:
Biomarker:EZH2 mutation
Cancer:Diffuse Large B Cell Lymphoma
Drug:CPI-169 (EZH2 inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Title:

Abstract 2925: Safety and efficacy of EZH2 and BRD4 dual targeting in EZH2Y641mut germinal centre-derived lymphoma

Published date:
05/15/2020
Excerpt:
CPI169 induced dose-dependent proliferation blockade in EZH2mut, but not EZH2wt DLBCL and FL cell lines, independently of EZH2 expression level…CPI169 shows significant activity and safety as single agent in EZH2 mutated-DLBCL and FL cases...
DOI:
10.1158/1538-7445.AM2020-2925